stocktools
fair-value calculator // DCF · reverse DCF · GrahamFREE

What’s a stock actually worth?

Three classic estimates — a two-stage DCF, a reverse DCF, and the Graham number — computed from a company’s own SEC filings, with every assumption editable and every input shown. The opposite of a proprietary “fair value” you can’t check.

cmmb · Chemomab Therapeutics Ltd.Full workspace →
FAIR-VALUE RANGE
$7.45
CURRENT PRICE
$1.15
MARGIN OF SAFETY (vs mid)
+548%
TWO-STAGE DCF
—
8% growth for 10y, 2.5% terminal, 9% discount
GRAHAM NUMBERBenjamin Graham's ceiling for a cautious buyer: the highest share price his 1949 rule allows, at 15 times earnings and 1.5 times book value combined. A yardstick, not a forecast.
$7.45
+548% vs price
√(22.5 × EPS × book value/share)
REVERSE DCF
—
FCF growth the current price implies for 10y.
YOUR ASSUMPTIONS — TWEAK ANYTHING

No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.

Plain English for every number above. One AI generation, or free if someone already asked about these numbers.
THE INPUTS — FROM CMMB’S FILINGS, FY ENDING 2025-12-31
Free cash flow $-11.1MADSs 0.01BDiluted EPS per ADS $1.44Book value/ADS $1.71

Per ADS: one ADS is 80 ordinary shares (20-F filed 2026-03-23), so EPS and book value are multiplied by 80 and the share count divided by it.

Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from CMMB’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.

your saved valuations // stale when a newer filing changes an input

Loading your saved valuations…

A DCF is only as good as its assumptions — that’s exactly why every one here is yours to change. We treat free cash flow as cash flow to equity and divide by shares (the common retail shortcut; it skips net debt and a full WACC), so treat the output as a sanity-check range, not a valuation opinion. Inputs from SEC filings. Educational only — not investment advice.